SUN PHARMACEUTICAL INDUSTRIES INC recalls
18 notices naming SUN PHARMACEUTICAL INDUSTRIES INC as the recalling firm, since March 12, 2025. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
SUN PHARMACEUTICAL INDUSTRIES INC: Tretinoin Cream USP and 2 more
Hazard (FDA): Failed Impurities/Degradation Specifications
FDAMedicines
Burn
SUN PHARMACEUTICAL INDUSTRIES INC: Carbamazepine Tablets
Hazard (FDA): CGMP Deviations; black spots found on tablets from burnt excipient during manufacturing
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Fexofenadine Hydrochloride Tablets
Hazard (FDA): Failed Impurities/Degradation Specifications
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Perampanel CIII Tablets
Hazard (FDA): Labeling: Label Mix-up: 10mg Perampanel CIII tablet was found in a Perampanel CIII bottle labeled Perampanel 6 mg tablets.
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Budesonide Inhalation Suspension
Hazard (FDA): Presence of Foreign Substance:This recall has been initiated in response to a product quality complaint reported for black/brown specs and particles within the ampoule solution
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: DOXOrubin Hydrochloride Liposome injection
Hazard (FDA): Presence of Particulate matter: Particulate matter identified as glass.
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Xyvona and 1 more
Hazard (FDA): Labeling: Not Elsewhere Classified. This recall has been initiated in response to the denial by FDA of marketing the product under the proprietary name Xyvona
FDAMedicines
Sun Pharmaceutical Industries, Inc. (Sun Pharma) Initiates Voluntary U.S. Nationwide Recall of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL Due To Potential Presence of Glass Particles
Hazard (FDA): Presence of glass particles
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Fluocinonide and 2 more
Hazard (FDA): Failed Viscosity Specifications: Out of Specification results, above the specification limit, in viscosity, noted during stability testing.
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Diclofenac Sodium
Hazard (FDA): Failed Viscosity Specifications: Out of Specification (OOS) [slightly lower than the limit] result in viscosity for Diclofenac Sodium Gel, 3%.
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Fluocinolone Acetonide Solution Topical Solution USP
Hazard (FDA): Failed Impurities/Degradation Specifications: Out of specification result was obtained for the known impurity D.
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Clindamycin Phosphate USP
Hazard (FDA): Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.
FDAMedicines
Dissolution
SUN PHARMACEUTICAL INDUSTRIES INC: Lisdexamfetamine Dimesylate Capsules and 6 more
Hazard (FDA): Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 60%RH) for Lisdexamfetamine dimesylate capsules.
FDAMedicines
Dissolution
SUN PHARMACEUTICAL INDUSTRIES INC: Kit for the Preparation of Technetium Tc 99m Mertiatide
Hazard (FDA): Failed Dissolution Specifications-Out of Specification (OOS) observation for sulphate in Sodium Tartrate Dihydrate used for the production of Mertiatide.
FDAMedicines
SUN PHARMACEUTICAL INDUSTRIES INC: Spironolactone Tablets
Hazard (FDA): Presence of foreign substance: identified as aluminum.
FDAMedicines
Dissolution
SUN PHARMACEUTICAL INDUSTRIES INC: Lisdexamfetamine Dimesylate Capsules
Hazard (FDA): Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 9 month long term stability station (25¿C, 60%RH).
FDAMedicines
Contamination
SUN PHARMACEUTICAL INDUSTRIES INC: Gabapentin Capsules and 1 more
Hazard (FDA): Cross Contamination
FDAMedicines
Dissolution
SUN PHARMACEUTICAL INDUSTRIES INC: Morphine Sulfate Extended-Release Tablets
Hazard (FDA): Failed Dissolution Specifications
FDAMedicines